Episodes
Turning the Tables, Rob Perez Interviews Me
Published 09/19/23
Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders
Published 09/06/23
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Published 08/24/23
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Published 08/08/23
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Published 07/24/23
Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Published 07/10/23
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Published 06/27/23
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Published 06/14/23
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
Published 05/30/23
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Published 05/08/23
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Published 04/24/23
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Published 04/12/23
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Published 03/28/23
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Published 03/14/23
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Published 02/28/23
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Published 02/14/23
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Published 02/01/23
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
Published 01/20/23
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Published 01/03/23
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Published 12/19/22
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
Published 11/08/22
Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.
Published 10/27/22
Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.
Published 10/11/22
Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.
Published 09/26/22
Tim Lu, CEO of Senti Biosciences, on developing gene circuits for cell therapy.
Published 09/07/22
Listen now
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
